ARIAD Pharmaceuticals, Inc. ARIA today announced that the
Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines
Agency (EMA) has provided the Company with a request for limited additional
information regarding Iclusig^® (ponatinib) as part of its ongoing review
under the Article 20 referral procedure. The PRAC has requested further
information regarding proposed dose modifications after achievement of a
response and patient monitoring and details concerning a risk management plan.
Following ARIAD's response and input from the agency's Scientific Advisory
Group, the Company expects that the PRAC will complete its review and make
final recommendations to the Committee for Medicinal Products for Human Use
(CHMP) at its meeting in October 2014.
“As we finalize our recommendations on dose modifications of Iclusig and
response monitoring of patients, we will work closely with the European
regulatory agency and its expert advisors so that CML patients and their
treating physicians have the best guidance available supporting the
appropriate use of Iclusig,” said Timothy P. Clackson, Ph.D., president of
research and development and chief scientific officer at ARIAD.
In March 2014 ARIAD submitted responses to initial questions outlined by the
PRAC as part of the Article 20 process, which was initiated in December of
last year, and responses to a second set of questions were submitted to the
PRAC in June.
The authorized indications of Iclusig in Europe, as approved in July 2013,
remain as follows:
* The treatment of adult patients with chronic phase, accelerated phase or
blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib
or nilotinib; who are intolerant to dasatinib or nilotinib and for whom
subsequent treatment with imatinib is not clinically appropriate; or who
have the T315I mutation, or
* The treatment of adult patients with Philadelphia-chromosome positive
acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib;
who are intolerant to dasatinib and for whom subsequent treatment with
imatinib is not clinically appropriate; or who have the T315I mutation.
To view the Iclusig Summary of Medicinal Product Characteristics, click here.
The PRAC is the committee at the EMA that is responsible for assessing and
monitoring safety issues for human medicines. The PRAC's recommendations are
considered by the CHMP when it adopts opinions for centrally authorized
medicines and referral procedures.
About CML and Ph+ ALL
CML is a cancer of the white blood cells that is diagnosed in approximately
7,000 patients each year in Europe^[1]. CML is characterized by an excessive
and unregulated production of white blood cells by the bone marrow due to a
genetic abnormality that produces the BCR-ABL protein. After a chronic phase
of production of too many white blood cells, CML typically evolves to the more
aggressive phases referred to as accelerated phase and blast crisis. Ph+ ALL
is a subtype of acute lymphoblastic leukaemia that carries the Ph+ chromosome
that produces BCR-ABL. It has a more aggressive course than CML and is often
treated with a combination of chemotherapy and tyrosine kinase inhibitors. The
BCR-ABL protein is expressed in both of these diseases.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in